Telmisartan
- Generic Name
- Telmisartan
- Brand Names
- Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta, Tolura, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Telmisartan Teva Pharma, Telmisartan Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C33H30N4O2
- CAS Number
- 144701-48-4
- Unique Ingredient Identifier
- U5SYW473RQ
- Background
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arter...
- Indication
Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hypertension
- Associated Therapies
- -
Bioequivalence of Telmisartan/g Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT02214992
Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT02214979
Steady State Pharmacokinetics of Telmisartan, Ramipril or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT02215005
The Use of Angiotensin Receptor Blockers and the Risk of Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1165781
- Registration Number
- NCT02215733
Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 180
- Registration Number
- NCT02213224
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, GuangZhou, Guangdong, China
Bioavailability of Lacidipine and Telmisartan Fixed Dose Combination Tablets Relative to Separate Tablets in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02209649
Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02206659
Tolerability and Pharmacokinetics of Lacidipine With and Without the Co-administration of Telmisartan in Female and Male Healthy Subjects
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT02203500
Pharmacovigilance and Patient Compliance in Hypertensive Patients
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 10333
- Registration Number
- NCT02200575
Bioequivalence of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT02193308
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.